Protein tyrosine phosphatases (PTPS) as drug targets: Inhibitors of PTP-1B for the treatment of diabetes

Current Opinion in Drug Discovery and Development

Volumn 3, Issue 5, 2000, Pages 527-540

  Hundahl Moller, N P ^a   Iversen, L F ^a   Andersen, H S ^a   McCormack, J G ^a  

^a NOVO NORDISK A S   (Denmark)

Author keywords

Diabetes; Insulin sensitivity; Insulin signaling; Phosphorylation; Protein tyrosine phosphatase 1B; Tyrosine

Indexed keywords

2 (OXALYLAMINO)BENZOIC ACID; ACID PHOSPHATASE; ANTISENSE OLIGONUCLEOTIDE; CD45 ANTIGEN; GLUCOSE; INSULIN; INSULIN RECEPTOR; INSULIN RECEPTOR KINASE; ISOENZYME; LEPTIN; NAPHTHALENE DERIVATIVE; PROTEIN TYROSINE PHOSPHATASE; PROTEIN TYROSINE PHOSPHATASE 1B; PROTEIN TYROSINE PHOSPHATASE INHIBITOR; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; VANADIUM DERIVATIVE;

DIABETES MELLITUS; DRUG DESIGN; DRUG RECEPTOR BINDING; DRUG SCREENING; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; GLUCOSE HOMEOSTASIS; HUMAN; INSULIN SENSITIVITY; KNOCKOUT MOUSE; NONHUMAN; PROTEIN DOMAIN; REVIEW; SIGNAL TRANSDUCTION;

EID: 0033778926     PISSN: 13676733     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (115)

1. Protein tyrosine phosphateses: A diverse family of intracellular and transmembrane enzymes
2. Signaling - 2000 and beyond
3. Crystal structure of the activated insulin-receptor tyrosine kinase in complex with peptide substrate and ATP analog
4. Protein tyrosine phosphatases: Their role in insulin action and potential as drug targets
5. Regulation of insulin action by protein tyrosine phosphatases
6. Increased insulin sensitivity and obesity resistance in mice lacking the protein tyrosine phosphatese-1B gene
7. Increased energy expenditure, decreased adiposity, and tissue-specific insulin sensitivity in protein tyrosine phosphatase 1B-deficient mice
8. Selective down-regulation of the insulin receptor signal by protein tyrosine phosphatases α and ε
9. The next wave: Protein tyrosine phosphatases enter T-cell antigen receptor signaling
10. Calpain-catalyzed cleavage and subceliular relocation of protein phosphotyrosine phosphatase 1B (PTP-1B) in human platelets
11. Protein tyrosine phosphatase activity regulates osteoclast formation and function - Inhibition by alendronate
12. 1-Naphthylmethylphosphonic acid derivatives as osteoclastic acid phosphatese inhibitors
13. Emerging issues in receptor protein tyrosine phosphatase function: Lifting fog or simply shifting?
14. Cdc25 as a potential target of anticancer agents
15. Microbial pathogenesis and tyrosine dephosphorylation: Surprising 'bedfellows'
16. A thousand and two protein tyrosine phosphatases
17. 1002 Protein phosphatases?
18. Genome sequence of the nematode C elegens: A platform for investigating biology
19. Protein tyrosine phosphatases in signal transduction
20. Characterization of the major protein tyrosine phosphateses of human placenta
21. Purification of the major protein tyrosine phosphatases of human placenta
22. Human placenta protein tyrosine phosphatase: Amino acid sequence and relationship to a family of receptor-like proteins
23. Role of protein tyrosine phosphatase-1B in diabetes and obesity
24. Sequential dephosphorylation of a multiply phosphorylated insulin receptor peptide by protein tyrosine phosphatases
25. Expression of protein tyrosine phosphatases in the major insulin target tissues
26. Purification, identification and subcellular distribution of three predominant protein tyrosine phosphatase enzymes in skeletal muscle tissue
27. Differential activities of protein tyrosine phosphatases in intact cells
28. Overexpression of protein tyrosine phosphatase-α (PTP-α) but not PTP-κ inhibits translocation of GLUT4 in rat adipose celts
29. Receptor-like protein tyrosine phosphatase α specifically inhibits insulin-increased prolactin gene expression
30. Microinjection of a protein tyrosine phosphatase inhibits insulin action in Xenopus oocytes
31. Osmotic loading of neutralizing antibodies demonstrates a role for protein tyrosine phosphatase 1B in negative regulation of the insulin action pathway
32. Insulin receptor signaling is augmented by antisense inhibition of the protein tyrosine phosphatase LAR
33. Identification of tyrosine phosphatases that dephosphorylate the insulin receptor. A brute force approach based on 'substrate-trapping' mutants
34. Development of 'substrate-trapping' mutants to identify physiological substrates of protein tyrosine phosphatases
35. Structural diversity and evolution of human receptor-like protein tyrosine phosphatases
36. A new member of the immunoglobulin superfamily that has a cytoplasmic region homologous to the leukocyte common antigen
37. Targeted disruption of the tyrosine phosphatase PTPα leads to constitutive downregulation of the kinases Src and Fyn
38. Receptor protein tyrosine phosphatase α activates Src- family kinases and controls integrin-mediated responses in fibroblasts
39. Transonic mice deficient in the LAR protein tyrosine phosphatase exhibit profound defects in glucose homeostasis
40. Impaired mammary gland development and function in mice lacking LAR receptor-like tyrosine phosphatase activity
41. Insulin responsiveness in mice lacking LAR protein phosphatase activity
42. Insulin sensitizer drugs
43. Identification of a second aryl phosphate-binding site in protein tyrosine phosphatase 1B: A paradigm for inhibitor design
44. Residue 259 is a key determinant of substrate specificity of protein tyrosine phosphatases 1B and α
45. Parvanadate [peroxide(s) of vanadate] mimics insulin action in rat adipocytes via activation of the insulin receptor tyrosine kinase
46. Peroxovanadium compounds: Biological actions and mechanism of insulin mimesis
47. Peroxyvanadium compounds inhibit glucose-6-phosphatase activity and glucagon-stimulated hepatic glucose output an the rat in vivo
48. Oral vanadyi sulfate improves hepatic and peripheral insulin sensitivity in patients with non-insulin-dependent diabetes mellitus
49. In vivo and in vitro studies of vanadate in human and rodent diabetes nnellitus
50. Protein tyrosine phosphatases: Structure, mechanism, and inhibitor discovery
51. Structure-based design and synthesis of small molecule protein tyrosine phosphatase inhibitors
52. Potent Inhibition of protein tyrosine phosphatase by phosphotyrosine mimic-containing cyclic peptides
53. Small molecule interactions with protein tyrosine phosphatase PTP1B and their use in inhibitor design
54. Potent and highly selective inhibitors of the protein tyrosine phosphatase 1B
55. Crystal structure of human protein tyrosine phosphatase 1B
56. Crystal structure of the catalytic domain of protein tyrosine phosphatase SHP-1
57. Crystal structure of the tyrosine phosphatase SHP-2
58. Structural basis for inhibition of receptor protein tyrosine phosphatase α by dimerization
59. The crystal structure of domain 1 of receptor protein tyrosine phosphatase μ
60. Crystal structure of the tandem phosphatase domains of RPTP LAR
61. Crystal structure of Yersinia protein tyrosine phosphatase at 2.5 Å and the complex with tungstate
62. Crystal structure of the duel specificity protein phosphatase VHR
63. Crystal structure of the MAPK phosphatase Pyst1 catalytic domain and implications for regulated activation
64. Crystal structure of the catalytic subunit of Cdc25B required for G2/M phase transition of the cell cycle
65. Crystal structure of the catalytic domain of the human cell cycle control phosphatase, Cdc25A
66. The structure of the bovine protein tyrosine phosphatase dimer reveals a potential self-regulation mechanism
67. Crystal structure of the PTEN tumor suppressor: Implications for its phospholnositide phosphatase activity and membrane association
68. Visualization of the cysteinyl-phosphata intermediate of a protein tyrosine phosphatase by X-ray crystallography
69. Structural basis for phosphotyrosine peptide recognition by protein tyrosine phosphatase 1B
70. Structural basis for inhibition of the protein tyrosine phosphatase 1B by phosphotyrosine peptide mimetics
71. 2-(Oxalylamino)-benzoic acid is a general, competitive inhibitor of protein tyrosine phosphatases
72. Structure-based design of a low molecular weight, non-phosphorus, non-peptide, and highly selective inhibitor of protein tyrosine phosphatase 1B
73. Hovel benzofuren and benzothiophene biphenyls as inhibitors of protein tyrosine phosphatase 1B with antihyperglycemic properties
74. Structural basis for substrata specificity of protein tyrosine phosphatase SHP-1
75. The crystal structure of a low molecular weight phosphotyrosine protein phosphatase
76. Crystal structure of a human low molecular weight phosphotyrosyl phosphatase. Implications for substrata specificity
77. Crystal structures of a low molecular weight protein tyrosine phosphatase from Saccharomyces cerevisiae and its complex with the substrata p-nitrophenyl phosphate
78. Structural and mechanistic basis for the activation of a low molecular weight protein tyrosine phosphatase by adenine
79. Crystal structure of bovine low molecular weight phosphotyrosyl phosphatase complexed with the transition state analog vanadate
80. Three-dimensional structure of rat acid-phosphatase
81. The X-ray crystal structures of Yersinia tyrosine phosphatase with bound tungstate and nitrate. Mechanistic implications
82. A ligand-induced conformational change in the Yersinia protein tyrosine phosphatase
83. Novel phosphate mimetics for the design of non-peptidyl inhibitors of protein tyrosine phosphatases
84. Naphthalenebis [α,α-difluoromethylenephosphonates] as potent inhibitors of protein tyrosine phosphatase
85. A general method for preparation of benzylic α,α-difluorophosphonic acids; non-hydrolyzable mimetics of phosphotyrosine
86. Potent non-peptidyl inhibitors of protein tyrosine phosphatase 1B
87. New azolldinediones as inhibitors of protein tyrosine phosphatase 1B with antihyperglycemic properties
88. PTP1B inhibition and antihyperglycemic activity in the ob/ob mouse model of novel 11-arylbenzo[b]naphtho[2,3-d]furans and 11-arylbenzo[b]naphtho[2,3-d]thiophenes
89. Synthesis and PTP1B inhibition of novel 4-aryl-1-oxa-9-thiacyclopenta[b]fluorenes